Yahoo Finance

ABLYNX'S PARTNER, MERCK KGaA, REPORTS ENCOURAGING RESULTS WITH THE BI-SPECIFIC NANOBODY ANTI-IL-17A/F (M1095) IN A PHASE Ib CLINICAL STUDY IN PATIENTS WITH ...

GHENT, Belgium, 26 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its partner, Merck KGaA (Darmstadt, Germany), has reported encouraging results from a study in ...
Yahoo Finance

ABLYNX'S PARTNER, MERCK KGaA, HAS PRESENTED NEW DATA FROM A PHASE Ib PSORIASIS STUDY OF THE BI-SPECIFIC ANTI-IL-17A/F NANOBODY AT THE ANNUAL AAD CONFERENCE

All patients in the highest dose group achieved 90% skin clearance (PASI 90) compared to 0% for placebo Skin biopsy showed complete reversal of disease pathology in the majority of patients in the ...
Business Insider

Avillion announces positive top-line results of Phase 2 trial of sonelokinab (M1095), an anti-IL-17 A/F Nanobody®, in chronic psoriasis

LONDON, Sept. 10, 2020 /PRNewswire/ -- Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory ...